2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study

P2.09. Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study - PDF(Abstract)

Back to course

Pdf Summary

A retrospective and exploratory study was conducted to evaluate the efficacy of Anlotinib in patients with non-small cell lung cancer (NSCLC) who developed resistance to Osimertinib, a targeted therapy for EGFR mutations. The study collected data from 268 NSCLC patients with the EGFR T790M mutation who had become resistant to Osimertinib and compared the efficacy of antiangiogenic-based therapy (using Anlotinib) with immunotherapy and chemotherapy.<br /><br />The results showed that patients receiving antiangiogenic-based therapy had a significantly longer progression-free survival (PFS) compared to those receiving immunotherapy or chemotherapy. The objective response rate (ORR) and disease control rate (DCR) were also higher in the antiangiogenic-based therapy group.<br /><br />Subgroup analysis revealed that Anlotinib-based therapy may have more benefits in terms of PFS and overall survival (OS) compared to Bevacizumab-based therapy. In in vitro experiments, Anlotinib alone or in combination with Osimertinib demonstrated potent cytotoxicity to T790M-mutant NSCLC cells with acquired Osimertinib resistance.<br /><br />These findings suggest that antiangiogenic-based therapy, particularly using Anlotinib, could be an effective treatment option for EGFR-mutant NSCLC patients who have developed resistance to Osimertinib. The study highlights the potential of targeting angiogenesis in the treatment of Osimertinib-resistant NSCLC. These results have implications for the management of patients with metastatic NSCLC and provide valuable insights for future treatment strategies.

Asset Subtitle

Ya Chen

Meta Tag

Speaker Ya Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Anlotinib

NSCLC

Osimertinib resistance

antiangiogenic-based therapy

immunotherapy

chemotherapy

progression-free survival

EGFR mutations

cytotoxicity

angiogenesis